Topically administered janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis

Journal of Pharmacology and Experimental Therapeutics

Volumn 354, Issue 3, 2015, Pages 394-405

  Fukuyama, Tomoki ^a   Ehling, Sarah ^a   Cook, Elizabeth ^a   Bäumer, Wolfgang ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 31; INTERLEUKIN 4; INTERLEUKIN 6; OCLACITINIB; THYMIC STROMAL LYMPHOPOIETIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TOFACITINIB; TOLUENE DIISOCYANATE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTIPRURITIC AGENT; JANUS KINASE; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; EAR EDEMA; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PRURITUS; SCRATCHING; SKIN ALLERGY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DERMATITIS, ALLERGIC CONTACT; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; LYMPH NODE; METABOLISM; ORAL DRUG ADMINISTRATION; SKIN; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIPRURITICS; CYTOKINES; DERMATITIS, ALLERGIC CONTACT; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; JANUS KINASES; LYMPH NODES; MICE; MICE, INBRED BALB C; PIPERIDINES; PRURITUS; PYRIMIDINES; PYRROLES; SKIN; SULFONAMIDES;

EID: 84941565609     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.223784     Document Type: Article

References (44)

1. Aslam I, Sandoval LF, and Feldman SR (2014) What's new in the topical treatment of allergic skin diseases. Curr Opin Allergy Clin Immunol 14:436-450.
2. Balagué C, Pont M, Prats N, and Godessart N (2012) Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: A translational study. Br J Pharmacol 166:1320-1332.
3. Ban M, Morel G, Langonné I, Huguet N, Pépin E, and Binet S (2006) TDI can induce respiratory allergy with Th2-dominated response in mice. Toxicology 218:39-47.
4. Bäumer W, Seegers U, Braun M, Tschernig T, and Kietzmann M (2004) TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis. Effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines. Br J Dermatol 151:823-830.
5. Bäumer W, Tschernig T, Sülzle B, Seegers U, Lührmann A, and Kietzmann M (2003) Effects of cilomilast on dendritic cell function in contact sensitivity and dendritic cell migration through skin. Eur J Pharmacol 481:271-279.
6. Bissonnette R, Iversen L, Sofen H, Griffiths CEM, Foley P, Romiti R, Bachinsky M, Rottinghaus ST, Tan H, Proulx J, et al. (2015) Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A randomized controlled trial. Br J Dermatol 172:1395-1406.
7. Boy MG, Wang C, Wilkinson BE, Chow VF, Clucas AT, Krueger JG, Gaweco AS, Zwillich SH, Changelian PS, and Chan G (2009) Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690, 550 in patients with psoriasis. J Invest Dermatol 129:2299-2302.
8. Cevikbas F, Wang X, Akiyama T, Kempkes C, Savinko T, Antal A, Kukova G, Buhl T, Ikoma A, Buddenkotte J, et al. (2014) A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. J Allergy Clin Immunol 133:448-460.
9. Chen T, Guo J, Yang M, Han C, Zhang M, Chen W, Liu Q, Wang J, and Cao X (2004) Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression. Blood 103:413-421.
10. Collard WT, Hummel BD, Fielder AF, King VL, Boucher JF, Mullins MA, Malpas PB, and Stegemann MR (2014) The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. J Vet Pharmacol Ther 37:279-285.
11. Cosgrove SB, Wren JA, Cleaver DM, Martin DD, Walsh KF, Harfst JA, Follis SL, King VL, Boucher JF, and Stegemann MR (2013a) Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 24:e479-e114.
12. Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JKS, and Stegemann MR (2013b) A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in clientowned dogs with atopic dermatitis. Vet Dermatol 24:e587-e142.
13. Dowty ME, Jesson MI, Ghosh S, Lee J, Meyer DM, Krishnaswami S, and Kishore N (2014) Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J Pharmacol Exp Ther 348:165-173.
14. Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, Contel N, Haley P, Thomas B, Shi J, et al. (2011) Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 131:1838-1844.
15. Fujii Y and Sengoku T (2013) Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis. Pharmacology 91:207-213.
16. Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, and Mitton-Fry M (2014) Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther 37:317-324.
17. Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, and Brossart P (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122:1192-1202.
18. Hijnen DJ, ten Berge O, Timmer-de Mik L, Bruijnzeel-Koomen CA, and de Bruin-Weller MS (2007) Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol 21:85-89.
19. Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, and Elbe-Bürger A (2004) Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 122:673-684.
20. Homey B, Assmann T, Vohr HW, Ulrich P, Lauerma AI, Ruzicka T, Lehmann P, and Schuppe HC (1998) Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol 160:5331-5340.
21. Isaacs JD, Zuckerman A, Krishnaswami S, Nduaka C, Lan S, Hutmacher MM, Boy MG, Kowalski K, Menon S, and Riese R (2014) Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: Results from clinical trials. Arthritis Res Ther 16:R158.
22. Kimata H (1999) Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Ann Allergy Asthma Immunol 82:293-295.
23. Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, and Tanaka Y (2014) The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 73:2192-2198.
24. Kudlacz E, Perry B, Sawyer P, Conklyn M, McCurdy S, Brissette W, Flanagan M, and Changelian P (2004) The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 4:51-57.
25. Lutz MB, Kukutsch N, Ogilvie AL, Rössner S, Koch F, Romani N, and Schuler G (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223:77-92.
26. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, et al. (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690, 550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 7:41.
27. Nakagawa R, Yoshida H, Asakawa M, Tamiya T, Inoue N, Morita R, Inoue H, Nakao A, and Yoshimura A (2011) Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC/Nga mice via suppression of Th2 and enhancement of Th17. J Immunol 187:4611-4620.
28. O'Shea JJ, Pesu M, Borie DC, and Changelian PS (2004) A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nat Rev Drug Discov 3: 555-564.
29. Panhans-Gross A, Novak N, Kraft S, and Bieber T (2001) Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 107:345-352.
30. Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, and Papp K (2013) A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 169:137-145.
31. Ratzinger G, Stoitzner P, Ebner S, Lutz MB, Layton GT, Rainer C, Senior RM, Shipley JM, Fritsch P, Schuler G, et al. (2002) Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol 168:4361-4371.
32. Reines I, Kietzmann M, Mischke R, Tschernig T, Lüth A, Kleuser B, and Bäumer W (2009) Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration. J Invest Dermatol 129:1954-1962.
33. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler U, Lipozencic J, Luger T, Oranje AP, et al.; European Dermatology Forum; European Academy of Dermatology and Venereology; European Task Force on Atopic Dermatitis; European Federation of Allergy; European Society of Pediatric Dermatology; Global Allergy and Asthma European Network (2012) Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 26:1176-1193.
34. Rivas-Caicedo A, Soldevila G, Fortoul TI, Castell-Rodríguez A, Flores-Romo L, and García-Zepeda EA (2009) Jak3 is involved in dendritic cell maturation and CCR7-dependent migration. PLoS One 4:e7066.
35. Rossbach K, Wendorff S, Sander K, Stark H, Gutzmer R, Werfel T, Kietzmann M, and Bäumer W (2009) Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 18:57-63.
36. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, and Niezychowski W; Study A3921063 Investigators (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367:616-624.
37. Steinman RM (2007) Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. Nat Med 13:1155-1159.
38. Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, et al. (2015) Pharmacological properties of JTE-052: A novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res 64:41-51.
39. Trinh HT, Shin YW, Han SJ, Han MJ, and Kim DH (2008) Evaluation of antipruritic effects of red ginseng and its ingredients in mice. Planta Med 74:210-214.
40. Villarino AV, Kanno Y, Ferdinand JR, and O'Shea JJ (2015) Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 194:21-27.
41. Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, et al. (2012) Randomized phase 2b trial of tofacitinib (CP-690, 550) in de novo kidney transplant patients: Efficacy, renal function and safety at 1 year. Am J Transplant 12:2446-2456.
42. Wilson SR, Thé L, Batia LM, Beattie K, Katibah GE, McClain SP, Pellegrino M, Estandian DM, and Bautista DM (2013) The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 155:285-295.
43. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, Kawabata T, and Riese R (2014) Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66:2675-2684.
44. Yew-Booth L, Rastrick JM, Lau M, Evans SM, Kilty I, Belvisi MG, and Birrell MA (2012) The role of the JAK/STAT pathway in a lipopolysaccharide-induced mouse model of acute lung injury. Am J Respir Crit Care Med 185:A2089.